JP7650351B2 - 非古典的ｈｌａ－ｉとネオアンチゲンとを含む複合体を標的とする抗体、およびその使用方法 - Google Patents

非古典的ｈｌａ－ｉとネオアンチゲンとを含む複合体を標的とする抗体、およびその使用方法 Download PDF

Info

Publication number
JP7650351B2
JP7650351B2 JP2023517829A JP2023517829A JP7650351B2 JP 7650351 B2 JP7650351 B2 JP 7650351B2 JP 2023517829 A JP2023517829 A JP 2023517829A JP 2023517829 A JP2023517829 A JP 2023517829A JP 7650351 B2 JP7650351 B2 JP 7650351B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023517829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530036A (ja
JP2023530036A5 (cg-RX-API-DMAC10.html
Inventor
ワイダンツ，ジョン
アップチャーチ－アンジュ，キャサリン
Original Assignee
べーリンガー インゲルハイム インターナショナル ゲーエムベーハー
ベーリンガー インゲルハイム インターナショナル ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by べーリンガー インゲルハイム インターナショナル ゲーエムベーハー, ベーリンガー インゲルハイム インターナショナル ゲーエムベーハー filed Critical べーリンガー インゲルハイム インターナショナル ゲーエムベーハー
Publication of JP2023530036A publication Critical patent/JP2023530036A/ja
Publication of JP2023530036A5 publication Critical patent/JP2023530036A5/ja
Application granted granted Critical
Publication of JP7650351B2 publication Critical patent/JP7650351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2023517829A 2020-06-01 2021-06-01 非古典的ｈｌａ－ｉとネオアンチゲンとを含む複合体を標的とする抗体、およびその使用方法 Active JP7650351B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063032747P 2020-06-01 2020-06-01
US63/032,747 2020-06-01
US17/199,205 US11359023B2 (en) 2020-06-01 2021-03-11 Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US17/199,205 2021-03-11
PCT/US2021/035290 WO2021247607A1 (en) 2020-06-01 2021-06-01 Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use

Publications (3)

Publication Number Publication Date
JP2023530036A JP2023530036A (ja) 2023-07-12
JP2023530036A5 JP2023530036A5 (cg-RX-API-DMAC10.html) 2023-08-02
JP7650351B2 true JP7650351B2 (ja) 2025-03-24

Family

ID=75495114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517829A Active JP7650351B2 (ja) 2020-06-01 2021-06-01 非古典的ｈｌａ－ｉとネオアンチゲンとを含む複合体を標的とする抗体、およびその使用方法

Country Status (20)

Country Link
US (4) US10981996B1 (cg-RX-API-DMAC10.html)
EP (1) EP4157882A4 (cg-RX-API-DMAC10.html)
JP (1) JP7650351B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230019468A (cg-RX-API-DMAC10.html)
CN (1) CN116367865A (cg-RX-API-DMAC10.html)
AR (1) AR122501A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021284275A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022024275A2 (cg-RX-API-DMAC10.html)
CA (1) CA3174090A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022003336A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022018426A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220652A (cg-RX-API-DMAC10.html)
DO (1) DOP2022000268A (cg-RX-API-DMAC10.html)
EC (1) ECSP22097197A (cg-RX-API-DMAC10.html)
IL (1) IL298020A (cg-RX-API-DMAC10.html)
JO (1) JOP20220309A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022015114A (cg-RX-API-DMAC10.html)
PE (1) PE20230306A1 (cg-RX-API-DMAC10.html)
TW (1) TW202235439A (cg-RX-API-DMAC10.html)
WO (1) WO2021247607A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531255A (ja) * 2018-07-23 2021-11-18 アベクサ バイオロジクス，インク． 非古典的ｈｌａ−ｉおよびネオアンチゲンを含む複合体を標的とする抗体、およびその使用方法
WO2021236638A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US20250223363A1 (en) * 2022-04-08 2025-07-10 Tizona Therapeutics, Inc. Combination therapy involving anti-hla-g antibodies and anti-egfr antibodies, anti-pd1 or anti-pd-l1 antibodies, and/or anti-cd47

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140525A1 (en) 2017-01-24 2018-08-02 Abexxa Biologics, Inc. Methods and compositions for targeting a complex comprising non-classical hla-i and neoantigen in cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2010019921A2 (en) * 2008-08-15 2010-02-18 The Regents Of The University Of California Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
US9206257B2 (en) 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
CN104936985A (zh) 2013-02-26 2015-09-23 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
CN103773775B (zh) 2014-01-26 2015-11-18 江苏省农业科学院 一种人源抗虫基因及其编码的抗Cry1B毒素独特型单链抗体与应用
KR20170020868A (ko) 2014-06-20 2017-02-24 바이오얼라이언스 씨.브이. 항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
CN107660214B (zh) 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体
JP7054397B2 (ja) 2016-06-27 2022-04-13 ジュノー セラピューティクス インコーポレイテッド Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
CN112351795A (zh) 2018-02-23 2021-02-09 安贝科思生物制剂公司 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法
JP2021531255A (ja) 2018-07-23 2021-11-18 アベクサ バイオロジクス，インク． 非古典的ｈｌａ−ｉおよびネオアンチゲンを含む複合体を標的とする抗体、およびその使用方法
US20200291128A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US10981997B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981996B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140525A1 (en) 2017-01-24 2018-08-02 Abexxa Biologics, Inc. Methods and compositions for targeting a complex comprising non-classical hla-i and neoantigen in cancer

Also Published As

Publication number Publication date
CL2022003336A1 (es) 2023-06-23
US20220332831A1 (en) 2022-10-20
CA3174090A1 (en) 2021-12-09
WO2021247607A1 (en) 2021-12-09
MX2022015114A (es) 2023-03-24
DOP2022000268A (es) 2023-01-15
CR20220652A (es) 2023-07-03
PE20230306A1 (es) 2023-02-13
JOP20220309A1 (ar) 2022-11-15
IL298020A (en) 2023-01-01
ECSP22097197A (es) 2023-02-28
US20240026007A1 (en) 2024-01-25
BR112022024275A2 (pt) 2023-05-02
US10981996B1 (en) 2021-04-20
AR122501A1 (es) 2022-09-14
TW202235439A (zh) 2022-09-16
KR20230019468A (ko) 2023-02-08
JP2023530036A (ja) 2023-07-12
US20210371532A1 (en) 2021-12-02
CO2022018426A2 (es) 2022-12-30
US11359023B2 (en) 2022-06-14
CN116367865A (zh) 2023-06-30
US12173072B2 (en) 2024-12-24
AU2021284275A1 (en) 2023-01-19
EP4157882A1 (en) 2023-04-05
EP4157882A4 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
JP7545438B2 (ja) Ｖｉｓｔａ抗原結合性分子
JP7653513B2 (ja) 非古典的ｈｌａ－ｉとネオアンチゲンとを含む複合体を標的とする抗体、およびその使用方法
US9828432B2 (en) Cancer treatment and monitoring methods using OX40 agonists
KR102661066B1 (ko) 면역반응의 조절을 위한 방법 및 항체
US12173072B2 (en) Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
JP6794348B2 (ja) ヒト化抗ｏｘ４０抗体及びその使用
JP2020514363A (ja) 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５
US10981997B1 (en) Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
JP2020528765A (ja) 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用
JP2024535053A (ja) Ｖｉｓｔａ抗原結合性分子を使用する、がんの処置および防止
CN110662764A (zh) 抗程序性死亡配体1(pd-l1)抗体及其治疗用途
TWI790193B (zh) 調控免疫反應之方法及抗體
JP2019531703A (ja) 腫瘍関連マクロファージを標的化する抗体及びその使用
TW202235440A (zh) 靶向包含非典型hla-i及新生抗原之複合物的抗體及其使用方法
WO2024035341A1 (en) Cd30 antigen-binding molecules
KR20250152097A (ko) Btn3a 활성화 항체와 면역 체크포인트 억제제의 조합

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230725

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250311

R150 Certificate of patent or registration of utility model

Ref document number: 7650351

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150